BeiGene and Novartis expand cooperation!

Recently, BeiGene announced that it has reached an agreement on options, cooperation and licensing with Novartis Pharmaceuticals Group.
The two parties will jointly develop, produce and commercialize BeiGene's research TIGIT inhibitor ociperlimab in North America, Europe and Japan
.
Public information shows that Ociperlimab is a humanized IgG1 monoclonal antibody under investigation, independently developed by BeiGene and developed globally
.
As an immune checkpoint drug candidate, Ociperlimab is one of the most advanced anti-TIGIT antibodies in the current development process, with complete Fc function
.
It is reported that the Fc segment is essential for the anti-tumor activity of TIGIT antibodies
.
According to the agreement, in terms of ociperlimab, BeiGene will receive a cash advance of US$300 million from Novartis after the cooperation between the two parties, and Novartis will exercise its exclusive, time-based The option to obtain an additional 600 million or 700 million US dollars in payment, but this depends on obtaining the required antitrust approval
.
In addition, after Novartis exercises the option, BeiGene will also be entitled to up to US$745 million in pharmaceutical regulatory approval milestone payments, US$1.
15 billion in sales milestone payments, and royalties based on Ociperlimab’s sales in licensed regions.
Fee
.
It should be noted that this is not the first cooperation between BeiGene and Novartis
.
On January 12 this year, BeiGene reached a cooperation and licensing agreement with Novartis to develop in multiple countries including the United States, Canada, Mexico, EU member states, the United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan.
, Production and commercialization of the anti-PD-1 antibody Bezean (Tilelizumab)
.
According to the agreement, BeiGene received an advance payment of US$650 million and is eligible to receive a payment of up to US$1.
3 billion after reaching the registration milestone event, receiving a payment of US$250 million after reaching the sales milestone event, and being eligible for a substitute mine Royalties for future sales of Linibizumab in authorized regions
.
Analysts believe that the expansion of cooperation between BeiGene and Novartis is mainly due to the successful cooperation between BeiGene® and the current domestic PD-1/PD-L1 circuit competition
.
It is reported that as of now, there are a total of 11 PD-1/PD-L1 models on the market in China
.
In addition, a total of 6 domestically-made PD-1/PD-L1 and 1 PD-1/CTLA-4 dual antibodies are in the market review stage
.
It is estimated that by the end of 2022, there will be a total of 17 PD-1/PD-L1 monoclonal antibodies and 1 PD-1/CTLA-4 dual antibody on the market in China
.
With the increasing number of domestic competitors and increasingly fierce market competition, domestic companies are accelerating the internationalization of blockbuster drugs
.
In this context, cooperation with multinational companies has become a trend
.
For this strategic cooperation, the industry is expected to accelerate the clinical development process of Ociperlimab and Baizian® in combination drugs
.
It is worth mentioning that in addition to the in-depth cooperation on ociperlimab, in the agreement between the two parties, Novartis will also grant BeiGene a designated area (called "broad market") in China to market, promote and sell Tefila® ( Dabrafenib), meginine® (trametinib), vicante® (pazopanib), fenitor® (everolimus), and Zanko® (ceritinib), The rights to these 5 approved Novartis anti-tumor drugs
.
It is understood that these five Novartis anti-tumor drugs have been approved in China and have been included in the National Medical Insurance Drug List
.
In the future, BeiGene is expected to benefit from these drugs
.